Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1997 Feb;90(2):212–218. doi: 10.1046/j.1365-2567.1997.d01-2148.x

A comparative study of the in vitro immunomodulatory activity of human intact immunoglobulin (7S IVIG), F(ab')2 fragments (5S IVIG) and Fc fragments. Evidence for post-transcriptional IL-2 modulation.

D Nachbaur 1, M Herold 1, B Eibl 1, H Glassl 1, H Schwaighofer 1, C Huber 1, A Gächter 1, M Pichl 1, D Niederwieser 1
PMCID: PMC1456751  PMID: 9135549

Abstract

During the past few decades intravenous immunoglobulin (IVIG) has been used successfully in the treatment of various immunoregulatory disorders. Treatment results have been attributed to immunomodulation mainly via Fc receptors or by anti-idiotypic antibodies to disease-causing autoantibodies. From the present study it is clearly evident that 7S IVIG (intact immunoglobulin) as well as 5S IVIG [F(ab')2 fragments] and Fc fragments have a potent immunomodulatory capacity. We demonstrate that mainly 7S IVIG inhibits alloantigen-induced T-cell proliferation and generation of cytotoxic T lymphocytes. Reduced interleukin-2 (IL-2) protein levels in culture supernatants of IVIG-supplemented mixed lymphocyte reactions (MLR) but unchanged IL-2 mRNA levels strongly argue in favour of a post-transcriptional interference of IVIG with cytokines and/or cytokine production. Interferon-gamma (IFN-gamma), soluble IL-2 receptor (sIL-2R) and monokines such as IL-1 beta, IL-6, IFN-alpha and tumour necrosis factor (TNF-alpha) were not affected by IVIG supplementation to MLR. Fc fragments were superior to F(ab')2-containing IVIG (5S and 7S IVIG) in inhibiting lectin stimulation of peripheral blood mononuclear cells (PBMC), whereas natural killer (NK) cytotoxicity was primarily inhibited by Fc-bearing IVIG (7S IVIG and Fc fragments), suggesting multiple mechanisms of IVIG immunomodulatory activity.

Full text

PDF
212

Images in this article

215Figure 4
on p.215

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson U., Björk L., Skansén-Saphir U., Andersson J. Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol Rev. 1994 Jun;139:21–42. doi: 10.1111/j.1600-065x.1994.tb00855.x. [DOI] [PubMed] [Google Scholar]
  2. Aukrust P., Frøland S. S., Liabakk N. B., Müller F., Nordøy I., Haug C., Espevik T. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood. 1994 Oct 1;84(7):2136–2143. [PubMed] [Google Scholar]
  3. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  4. De Wit D., Van Mechelen M., Ryelandt M., Figueiredo A. C., Abramowicz D., Goldman M., Bazin H., Urbain J., Leo O. The injection of deaggregated gamma globulins in adult mice induces antigen-specific unresponsiveness of T helper type 1 but not type 2 lymphocytes. J Exp Med. 1992 Jan 1;175(1):9–14. doi: 10.1084/jem.175.1.9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Debré M., Bonnet M. C., Fridman W. H., Carosella E., Philippe N., Reinert P., Vilmer E., Kaplan C., Teillaud J. L., Griscelli C. Infusion of Fc gamma fragments for treatment of children with acute immune thrombocytopenic purpura. Lancet. 1993 Oct 16;342(8877):945–949. doi: 10.1016/0140-6736(93)92000-j. [DOI] [PubMed] [Google Scholar]
  6. Dietrich G., Kazatchkine M. D. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 1990 Mar;85(3):620–625. doi: 10.1172/JCI114483. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Durandy A., Fischer A., Griscelli C. Dysfunctions of pokeweed mitogen-stimulated T and B lymphocyte responses induced by gammaglobulin therapy. J Clin Invest. 1981 Mar;67(3):867–877. doi: 10.1172/JCI110104. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dwyer J. M. Manipulating the immune system with immune globulin. N Engl J Med. 1992 Jan 9;326(2):107–116. doi: 10.1056/NEJM199201093260206. [DOI] [PubMed] [Google Scholar]
  9. Feinberg A. P., Vogelstein B. "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem. 1984 Feb;137(1):266–267. doi: 10.1016/0003-2697(84)90381-6. [DOI] [PubMed] [Google Scholar]
  10. Feinberg A. P., Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem. 1983 Jul 1;132(1):6–13. doi: 10.1016/0003-2697(83)90418-9. [DOI] [PubMed] [Google Scholar]
  11. Gastl G., Niederwieser D., Marth C., Huber H., Egg D., Schuler G., Margreiter R., Braunsteiner H., Huber C. Human large granular lymphocytes and their relationship to natural killer cell activity in various disease states. Blood. 1984 Jul;64(1):288–295. [PubMed] [Google Scholar]
  12. Heeg K., Reimann J., Kabelitz D., Hardt C., Wagner H. A rapid colorimetric assay for the determination of IL-2-producing helper T cell frequencies. J Immunol Methods. 1985 Mar 18;77(2):237–246. doi: 10.1016/0022-1759(85)90036-5. [DOI] [PubMed] [Google Scholar]
  13. Huber C., Fink U., Leibold W., Schmalzl F., Peterson P. A., Klareskog L., Braunsteiner H. The role of adherent HLA-DR+ mononuclear cells in autologous and allogeneic MLR. J Immunol. 1981 Aug;127(2):726–731. [PubMed] [Google Scholar]
  14. Huber C., Irschik E., Leiter E., Binz H., Niederwieser D., Spielberger M., Kathrein H., Schönitzer D., Margreiter R. Use of donor-specific T-cell lines for monitoring of human allograft recipients. I. Demonstration of IgG binding to autologous TCL. Exp Cell Biol. 1986;54(1):16–24. doi: 10.1159/000163339. [DOI] [PubMed] [Google Scholar]
  15. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schöni M., Vest M., Wagner H. P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981 Jun 6;1(8232):1228–1231. doi: 10.1016/s0140-6736(81)92400-4. [DOI] [PubMed] [Google Scholar]
  16. Ishiguro A., Nakahata T., Koike K., Yoshida H., Shimbo T., Komiyama A. Induction of granulocyte and granulocyte-macrophage colony-stimulating factors from human monocytes stimulated by Fc fragments of human IgG. Br J Haematol. 1991 Sep;79(1):14–21. doi: 10.1111/j.1365-2141.1991.tb08000.x. [DOI] [PubMed] [Google Scholar]
  17. Kawada K., Terasaki P. I. Evidence for immunosuppression by high-dose gammaglobulin. Exp Hematol. 1987 Feb;15(2):133–136. [PubMed] [Google Scholar]
  18. Kimberly R. P., Salmon J. E., Bussel J. B., Crow M. K., Hilgartner M. W. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol. 1984 Feb;132(2):745–750. [PubMed] [Google Scholar]
  19. Ling Z. D., Ziltener H. J., Webb B. T., Matheson D. S. Aggregated immunoglobulin and Fc fragment of IgG induce IL-6 release from human monocytes. Cell Immunol. 1990 Aug;129(1):95–103. doi: 10.1016/0008-8749(90)90189-x. [DOI] [PubMed] [Google Scholar]
  20. Newburger J. W., Takahashi M., Burns J. C., Beiser A. S., Chung K. J., Duffy C. E., Glode M. P., Mason W. H., Reddy V., Sanders S. P. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986 Aug 7;315(6):341–347. doi: 10.1056/NEJM198608073150601. [DOI] [PubMed] [Google Scholar]
  21. Newland A. C. The use and mechanisms of action of intravenous immunoglobulin: an update. Br J Haematol. 1989 Jul;72(3):301–305. doi: 10.1111/j.1365-2141.1989.tb07708.x. [DOI] [PubMed] [Google Scholar]
  22. Passwell J., Rosen F. S., Merler E. The effect of Fc fragments of IgG on human mononuclear cell responses. Cell Immunol. 1980 Jul 1;52(2):395–403. doi: 10.1016/0008-8749(80)90360-3. [DOI] [PubMed] [Google Scholar]
  23. Ross C., Svenson M., Hansen M. B., Vejlsgaard G. L., Bendtzen K. High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG. J Clin Invest. 1995 May;95(5):1974–1978. doi: 10.1172/JCI117881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Römer J., Morgenthaler J. J., Scherz R., Skvaril F. Characterization of various immunoglobulin preparations for intravenous application. I. Protein composition and antibody content. Vox Sang. 1982 Feb;42(2):62–73. doi: 10.1159/000460850. [DOI] [PubMed] [Google Scholar]
  25. Rüfenacht R., Morell Immunochemical characterization of intravenous immunoglobulin preparations. Allergol Immunopathol (Madr) 1991 Sep-Oct;19(5):197–200. [PubMed] [Google Scholar]
  26. Salama A., Mueller-Eckhardt C., Kiefel V. Effect of intravenous immunoglobulin in immune thrombocytopenia. Lancet. 1983 Jul 23;2(8343):193–195. doi: 10.1016/s0140-6736(83)90175-7. [DOI] [PubMed] [Google Scholar]
  27. Scheurich P., Ucer U., Krönke M., Pfizenmaier K. Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer. 1986 Jul 15;38(1):127–133. doi: 10.1002/ijc.2910380120. [DOI] [PubMed] [Google Scholar]
  28. Sullivan K. M., Kopecky K. J., Jocom J., Fisher L., Buckner C. D., Meyers J. D., Counts G. W., Bowden R. A., Peterson F. B., Witherspoon R. P. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med. 1990 Sep 13;323(11):705–712. doi: 10.1056/NEJM199009133231103. [DOI] [PubMed] [Google Scholar]
  29. Sultan Y., Kazatchkine M. D., Maisonneuve P., Nydegger U. E. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet. 1984 Oct 6;2(8406):765–768. doi: 10.1016/s0140-6736(84)90701-3. [DOI] [PubMed] [Google Scholar]
  30. Svenson M., Hansen M. B., Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest. 1993 Nov;92(5):2533–2539. doi: 10.1172/JCI116862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Takei S., Arora Y. K., Walker S. M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest. 1993 Feb;91(2):602–607. doi: 10.1172/JCI116240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Tsubakio T., Kurata Y., Katagiri S., Kanakura Y., Tamaki T., Kuyama J., Kanayama Y., Yonezawa T., Tarui S. Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma-globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol. 1983 Sep;53(3):697–702. [PMC free article] [PubMed] [Google Scholar]
  33. Zier K. S., Huber C., Braunsteiner H. Linear density gradient separation of human lymphocyte subsets. I. Analysis by mixed leukocyte culture and cell-mediated lympholysis responses. Eur J Immunol. 1977 Jun;7(6):366–370. doi: 10.1002/eji.1830070608. [DOI] [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES